Summary
Marked, dose-dependent elevations in the urinary excretion of phenylethylamine, para-tyramine, and meta-tyramine were observed in depressed patients treated for three or more weeks with 10, 30, or 60 mg/ day of the partially-selective inhibitor of MAO-B, selegiline (1-deprenyl). In comparative studies with other, structurally similar acetylenic inhibitors of MAO, pargyline, an MAO-B > MAO-A inhibitor used in doses of 90mg/day for three or more weeks, produced elevations in these trace amines which were similar to those found with the highest dose of selegiline studied. Clorgyline, a selective inhibitor of MAO-A used in doses of 30mg/ day for three or more weeks (a dose/time regimen previously reported to reduce urinary, plasma, and cerebrospinal fluid 3-methoxy-4hydroxyphenylethyleneglycol (MHPG) > 80%, indicating a marked inhibitory effect on MAO-A in humans in vivo) produced negligible changes in trace amine excretion. In comparison to recent studies of individuals lacking the genes for MAO-A, MAO-B, or both MAO-A and MAO-B, the lack of change in trace amine excretion in individuals with a mutation affecting only MAO-A is in agreement with the observed lack of effect of clorgyline in the present study. Selegiline produced larger changes in trace amines — at least at the higher doses studied — than found in individuals lacking the gene for MAO-B, in agreement with other data suggesting a lesser selectivity for MAO-B inhibition when selegiline was given in doses higher than 10mg/day. Overall, trace amine elevations in individuals receiving the highest dose of deprenyl or receiving pargyline were approximately three to five-fold lower than the elevations observed in individuals lacking the genes for both MAOA and MAO-B, suggesting that these drug doses yield incomplete inhibition of MAO-A and MAO-B.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Boulton AA (1978) The tyramines: functionally significant biogenic amines or metabolic accident. Life Sci 23: 659–672
Celada P, Artigas F (1993) Monoamine oxidase inhibitors increase preferentially extracellular 5-hydroxytryptamine in the midbrain raphe nuclei. A brain microdialysis study in the awake rat. Naunyn Schmiedebergs Arch Pharmacol 347: 583–590
Davis BA, Boulton AA (1994) The trace amines and their acidic metabolites in depression — an overview. Prog Neuropsychopharmacol Biol Psychiatry 18: 17–45
de la Chapelle A, Sankila E-M, Lindlof M, Aula P, Norio R (1985) Norrie disease caused by a gene deletion allowing carrier detection and prenatal diagnosis. Clin Genet 28: 317–320
Eisler T, Teravainen H, Nelson R, Krebs H, Weise V, Lake CR, Ebert MH, Whetzel N, Murphy DL, Kopin IJ, Calne DB (1981) Deprenyl in Parkinson disease. Neurology 31: 19–23
Elsworth JD, Glover V, Reynolds GP, Sandler M, Lees AJ, Puapradit P, Shaw KM, Stern KM, Kumar P (1978) Deprenyl administration in man: a selective monoamine oxidase B inhibitor without the “cheese effect”. Psychopharmacology 57: 33–38
Feiner AE, Waldmeier PC (1979) Cumulative effects of irreversible MAO inhibitors in vivo. Biochem Pharmacol 28: 995–1002
Fowler CJ, Tipton KF (1984) On the substrate specificities of the two forms of monoamine oxidase. J Pharm Pharmacol 36: 111–115
Fowler CJ, Oreland L, Marcusson J, Winblad B (1980) Titration of human brain monoamine oxidase-A and-B by clorgyline and L-deprenyl. Naunyn Schmiedebergs Arch Pharmacol 311: 263–272
Fowler CJ, Mantle TJ, Tipton KF (1982) The nature of the inhibition of rat liver monoamine oxidase types A and B by the acetylenic inhibitors clorgyline, l-deprenyl and pargyline. Biochem Pharmacol 31: 3555–3561
Fuentes JA, Neff NH (1975) Selective monoamine oxidase inhibitor drugs as aids in evaluating the role of type A and B enzymes. Neuropharmacology 14: 819–825
Garrick NA, Scheinin M, Chang WH, Linnoila M, Murphy DL (1984) Differential effects of clorgyline on catecholamine and indoleamine metabolites in the cerebrospinal fluid of rhesus monkeys. Biochem Pharmacol 33: 1423–1427
Hsu YP, Powell JF, Sims KB, Breakefield XO (1989) Molecular genetics of the monoamine oxidases. J Neurochem 53: 12–18
Johnston JP (1968) Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem Pharmacol 17: 1285–1297
Karoum DF, Wyatt RJ (1982) Metabolism of (-)deprenyl’s therapeutic benefit: a biochemical assessment. Neurology 32: 503–509
Karoum F, Neff NH (1982) Quantitative gas chromatography-mass spectrometry (GC-MS) of biogenic amines. In: Spector S, Back N (eds) Theory and practice. Alan R Liss, New York, pp 39–54 (Modern Methods in Pharmacology)
Karoum F, Nasrallah H, Potkin S, Chuang L, Moyer-Schwing J, Phillips I, Wyatt RJ (1979) Mass fragmentography of phenylethylamine m-and p-tyramine, and related amines in plasma cerebrospinal fluid, urine, and brain. J Neurochem 33: 201–212
Karoum F, Potkin SG, Murphy DL, Wyatt RJ (1980) Quantiation and metabolism of phenylethylamine and tyramine’s three isomers in humnas. In: Mosnaim AD, Wolf ME (eds) Noncatecholic phenylethylamines. Marcel Dekker, New York, pp 177–191
Karoum F, Torrey EF, Murphy DL, Wyatt RJ (1985) The origin, drug interaction, urine, plasma and CSF concentrations of phenylacetic acid in normal and psychiatric subjects. In: Boulton AA, Baker GB, Dewhurst WG, Sandler M (eds) Neurobiology of the trace amine. Humana Press, Clifton NJ, pp 457–473
Lenders JWM, Eisenhofer G, Abeling NGGM, Berger W, Murphy DL, Konings CH, Wagemarkers LMB, Kopin IJ, Karoum F, van Gennip AH, Brunner HG (1996) Specific genetic deficiencies of the A and B isoenzymes of monoamine oxidase are characterized by distinct neurochemical and clinical phenotypes. J Clin Invest 97: 1–10
Liebowitz MR, Karoum Q FM, Davies SO, Schwartz D, Levitt M, Linnoila M (1985) Biochemical effects of L-deprenyl in atypical depressives. Biol Psychiatry 20: 558–565
Linnoila M, Karoum F, Potter WZ (1982) Effect of low-dose clorgyline on 24-hour urinary monoamine excretion in patients with rapidly cycling bipolar affective disorder. Arch Gen Psychiatry 39: 513–516
Lipper S, Murphy DL, Slater S, Buchsbaum MS (1979) Comparative behavioral effects of clorgyline and pargyline in man: a preliminary evaluation. Psychopharmacology 62: 123–128
Major LF, Murphy DL, Lipper S, Gordon E (1979) Effects of clorgyline and pargyline on deaminated metabolites of norepinephrine, dopamine and serotonin in human cerebrospinal fluid. J Neurochem 32: 229–231
Mann JJ, Aarons SF, Wilner PJ, Keilp JG, Sweeney JA, Pearlstein T, Frances AJ, Kocsis JH, Brown RP (1989) A controlled study of the antidepressant efficacy and side effects of (—)-deprenyl: a selective monoamine oxidase inhibitor. Arch Gen Psychiatry 46: 45–50
McKenna KF, Baker GB, Coutts RT (1993) Urinary excretion of bioactive amines and their metabolites in psychiatric patients receiving phenelzine. Neurochem Res 18: 1023–1027
Murphy DL (1978) Substrate-selective monoamine oxidases: inhibitor, tissue, species and functional differences. Biochem Pharmacol 27: 1889–1893
Murphy DL, Lipper S, Slater S, Shiling D (1979) Selectivity of clorgyline and pargyline as inhibitors of monoamine oxidases A and B in vivo in man. Psychopharmacology 62: 129–132
Murphy DL, Pickar D, Jimerson D, Cohen RM, Garrick NA, Karoum F, Wyatt RJ (1981) Biochemical indices of the effects of the selective MAO inhibitors clorgyline, pargyline and deprenyl in man. In: Usdin E, Dahl SG, Gram LF, Lingjaerde O (eds) Clinical pharmacology in psychiatry: neuroleptic and antidepressant research. Macmillan, London, pp 307–316
Murphy DL, Garrick NA, Cohen RM (1983) Monoamine oxidase inhibitors and monoamine oxidase: biochemical and physiological aspects relevant to human psychopharmacology. In: Burrows JD, Norman TR, Davies E (eds) Drugs in psychiatry. Antidepressants. Elsevier Press, Amsterdam, pp 209–227
Murphy DL, Garrick NA, Aulakh CS, Cohen RM (1984a) New contributions from basic science to understanding the effects of monoamine oxidase inhibiting antidepressants. J Clin Psychiatry 45: 37–43
Murphy DL, Karoum F, Alterman I, Lipper S, Wyatt RJ (1984b) Phenylethylamine, tyramine and other trace amines in patients with affective disorders: associations with clinical state and antidepressant drug treatment. In: Boulton AA, Baker GB, Dewhurst WG, Sandler M (eds) Neurobiology of the trace amines. Humana Press, Clifton NJ, pp 449–514
Murphy DT, Sunderland T, Cohen RM (1984c) Monoamine oxidase-inhibiting antidepressants: a clinical update. Psychiatr Clin North Am 7: 549–562
Murphy DL, Aulakh CS, Garrick NA, Sunderland T (1987) Monoamine oxidase inhibitors as antidepressants: implications for the mechanism of action of antidepressants and the psychobiology of the affective disorders and some related disorders. In: Meltzer HY (ed) Psychopharmacology: the third generation of progress. Raven Press, New York, pp 545–552
Murphy DL, Sims KB, Karoum F, de la Chapelle A, Norio R, Sankila E-M, Breakefield XO (1990) Marked amine and amine metabolite changes in Norrie disease patients with an X-chromosomal deletion affecting monoamine oxidase. J Neurochem 54: 242–247
Murphy DL, Sims KB, Karoum F, Garrick NA, de la Chapelle A, Sankila EM, Norio R, Breakefield XO (1991) Plasma amine oxidase activities in Norrie disease patients with an X-chromosomal deletion affecting monoamine oxidase. J Neural Transm [Gen Sect] 83: 1–12
Owen F, Cross AJ, Lofthouse R, Glover V (1979) Distribution and inhibition characteristics of human brain monoamine oxidase. Biochem Pharmacol 28: 1077–1080
Potter WZ, Murphy DL, Wehr TA, Linnoila M, Goodwin FK (1982) Clorgyline. A new treatment for patients with refractory rapid-cycling disorder. Arch Gen Psychiatry 39: 505–510
Potter WZ, Scheinin M, Golden RN, Rudorfer MV, Cowdry RW, Calil HM, Ross RJ, Linnoila M (1985) Selective antidepressants and cerebrospinal fluid. Arch Gen Psychiatry 42: 1171–1177
Quitkin FM, Liebowitz MR, Stewart JW, McGrath PJ, Harrison W, Rabkin JG, Markowitz J, Davies SO (1984) L-Deprenyl in atypical depressives. Arch Gen Psychiatry 41: 777–781
Sims KB, de la Chapelle A, Norio R, Sankila E-M, Hsu Y-PP, Rinehart WB, Corey TJ, Ozelius L, Powell JF, Bruns G, Gusella JF, Murphy DL, Breakefield XO (1989) Monoamine oxidase deficiency in males with an X chromosome deletion. Neuron 2: 1069–1076
Sunderland T, Mueller EA, Cohen RM, Jimerson DC, Pickar D, Murphy DL (1985) Tyramine pressor sensitivity changes during deprenyl treatment. Psychopharmacology 86: 432–437
Sunderland T, Cohen RM, Molchan S, Lawlor BA, Mellow AM, Newhouse PA, Tariot PN, Mueller EA, Murphy DL (1994) High dose selegiline in treatment-resistant older depressives. Arch Gen Psychiatry 51: 607–615
Weyler W, Hsu Y-P, Breakefield XO (1990) Biochemistry and genetics of monoamine oxidase. Pharmacol Ther 47: 391–417
Zametkin A, Rapoport JL, Murphy DL, Linnoila M, Karoum F, Potter WZ, Ismond D (1985) Treatment of hyperactive children with monoamine oxidase inhibitors. II. Plasma and urinary monoamine findings after treatment. Arch Gen Psychiatry 42: 969–973
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1998 Springer-Verlag Wien
About this paper
Cite this paper
Murphy, D.L. et al. (1998). Differential trace amine alterations in individuals receiving acetylenic inhibitors of MAO-A (clorgyline) or MAO-B (selegiline and pargyline). In: Finberg, J.P.M., Youdim, M.B.H., Riederer, P., Tipton, K.F. (eds) MAO — The Mother of all Amine Oxidases. Journal of Neural Transmission. Supplement, vol 52. Springer, Vienna. https://doi.org/10.1007/978-3-7091-6499-0_5
Download citation
DOI: https://doi.org/10.1007/978-3-7091-6499-0_5
Publisher Name: Springer, Vienna
Print ISBN: 978-3-211-83037-6
Online ISBN: 978-3-7091-6499-0
eBook Packages: Springer Book Archive